We tested the efficacy of our system by expressing the wt or
Introduction gene lead to amino acid changes, frame shifts and nonsense codons. 32 Using several in vitro assays, we previously examRegulation of cell cycle progression through the restriction (R) ined four missense alleles of p16 derived from tumors and point in the G 1 phase requires the concerted effort of numerthree deletion mutants lacking either portions of the COOHous cyclin-dependent kinases (CDKs), their respective cyclins terminal tail unique to the p16 protein (D136 and D141) or and cyclin-dependent kinase inhibitors (CDKIs). Dysregulation the fourth ankyrin (DA4) repeat ( Figure 1 ). 33 Two of these misof the R point plays a major role in tumorigenesis. [1] [2] [3] The sense point mutations, H83Y and G101W, functionally tumor suppressor pRb is an important regulator of the trancompromised p16 and the remaining two, E120K and R144C, sition from the G 1 to S phase. 4 Various transcription factors had no effects in vitro. This suggested that E120K and R144C that are required to activate S-phase genes are sequestered by were the result of sequence polymorphisms. Of the three underphosphorylated pRb (active). When pRb is phosphoryldeletion mutants, D136 and D141 appeared to function norated (inactive) at the R point in the G 1 phase, these factors are mally, but deletion of the fourth ankyrin repeat in DA4 comreleased and the cell progresses through the cell cycle. 4 pletely abrogated p16 function. 33 This suggested that the The CDK4 and CDK6 proteins are protein kinases that phos-COOH-terminal tail was not required for the p16 protein to phorylate pRb during the G 1 phase of the cell cycle. They bind CDK4, but the integrity of the ankyrin repeats was interact with the D-type cyclins to form an active kinase comessential.
To explore how these p16 gene mutations function in vivo in cells in culture and determine if p16 can inhibit leukemic cell growth, we utilized recombinant retroviruses containing Schematic diagram summarizing the wild-type and mutant forms of p16 protein examined in this study. The conserved ankyrin repeats (Ank1-Ank4) of p16 wt are located between amino acid residues 12 and 141 and are represented by the shaded boxes. The location of each point mutation is indicated below the p16 wt panel. The COOH-terminal tail (amino acid residues 141-156) present in p16 wt is absent in p15 wt and the p16 deletion mutant, D141. The p16 deletion mutant, DA4, lacks the Ank4 repeat (amino acid residues 110-141), but the COOH-terminal tail is fused in-frame with Ank3. The four ankyrin repeats in p15 wt are located between amino acid residues 14 and 137.
osteosarcoma cell line U20S (p16−, pRb+) to test the efficacy malian cells, the plasmids containing the mutant GAL4 DNAbinding domain-p16 fusion proteins 33 were digested with EagI of our system. Once we confirmed the utility of this approach, we infected p16-deficient leukemia cell lines and demonand SalI. The fragments were subcloned into pGEM-p16 digested with the same restriction enzymes. Then the resulting strated that restoration of p16 protein expression inhibits their growth dramatically; thus, supporting the hypothesis that p16
wild-type and mutant p16 genes ( Figure 1 ) were subcloned from pGEM3Z, using EcoRI and HindIII, into the retrovirus acts as a tumor suppressor in human leukemia. expression vector pSR␣MSVtkNeo; and a COS cell hyperexpression system, kindly provided by Charles Sawyers (Department of Hematology/Oncology, University of CaliforMaterials and methods nia, Los Angeles), was used to produce recombinant retrovirus stocks. 35 Titers were determined by infecting the osteosarCell lines coma cell line SAOS-2, which lacks a functional pRb, thereby allowing overexpression of p16, and evaluating the number The five human leukemia cell lines HSB-2 and CEM (T-ALLs), NB-4 (myelocytic leukemia), and K562 (erythroleukemia) of G418-resistant colony-forming units (G418-R CFU) per milliliter (ml). were cultured in RPMI 1640 medium supplemented with 10% (20% for CEM) fetal calf serum (FCS) and antibiotics (Gibco/BRL, Gaithersburg, MD, USA). COS-1 (SV-40 transforRetroviral infection and proliferation assays med African Green monkey kidney cells), and SAOS-2 and U2OS (human osteosarcoma cells) were cultured in DMEM For U2OS or SAOS-2, approximately 1 × 10 5 cells were supplemented with 10% FCS and antibiotics. All cell lines infected with equal amounts of virus in medium containing were obtained from American Type Culture Collection (ATCC, polybrene (8 g/ml) for 2 h, the medium was removed and Gaithersburg, MD, USA).
replaced with fresh medium. Approximately 48 h later, cells were cultured in medium containing 500 g/ml G418. The hematopoietic cells (2 × 10 5 ) were infected in a similar manGeneration of recombinant p16 retroviruses ner, but were cultured in two-layer soft agar containing G418 (CEM, 400 g/ml; HSB-2, 100 g/ml; NB4, 800 g/ml; K562, The coding region of p16
INK4A was amplified from a cDNA 400 g/ml) at 48 h post-infection as described previously. 36 In clone encoding the predicted amino acid sequence 34 using both cases, colonies with more than 50 cells were scored the polymerase chain reaction (PCR) with PFU polymerase 2 weeks later. For selection in liquid culture, HSB-2 and K562 (Stratagene, San Diego, CA, USA) and two primers, 5Ј-were infected as described above and 2 days post-infection GCGAATTCAGCAGCATGGATCCGG-3Ј and 5Ј-TGCTTGone-half of the cells were plated in 600 and 800 g/ml G418, TCATGAAGTCGAC-3Ј. The PCR product was digested with respectively, and cultured for 16 days. Total RNA was prethe EcoRI (5Ј end) restriction enzyme and subcloned into pared on days 2 and 16 as described below. pGEM3Z (Promega, Madison, WI, USA) cut with EcoRI and SmaI to produce pGEM-p16. The nucleotide sequence of the insert was verified by double-stranded DNA sequencing using Western blot and radioimmunoprecipitation analyses Sequenase (Amersham Life Sciences, Arlington Heights, IL, USA).
For Western blot analysis, cells were lysed in NP-40 (50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 0.5 or 1.0% NP-40) or RIPA To generate the mutant p16 genes for expression in mam-lysis buffer (50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 1.0% NP-N+ membrane (Amersham) as described by the manufacturer. The blot was hybridized with internal oligonucleotides against 40, 0.5% deoxycholate (DOC), 0.1% sodium dodecyl sulfate (SDS)). Protein content was determined using the Bradford either p16 (5Ј-GCCCAACGCACCGAATAGT-3Ј) or ␤-actin (5Ј-CTACAATGAGCTGCGTGTGGC-3Ј) that were end-labassay as described by the manufacturer (BioRad, Hercules, CA, USA). The cell lysates were electrophoresed through 12. 5 eled with 32 P␥ ATP using T4 kinase (Gibco/BRL) as described by the manufacturer. The final wash was in 0.1 × SSC, 0.1% or 15% polyacrylamide gels containing SDS and electrophoretically transferred to Immobilon-P membrane as described by SDS. The blot was exposed to XO-MAT AR film (Kodak 35 We initially tested the efficacy of these retroviruses in an osteosarcoma cell line, U2OS, that lacks 0.5% NP-40 for 30 min on ice, microfuged 10 min at 4°C and the resulting supernatant recovered and stored at −80°C until p16, but contains functional pRb. Overexpression of wt p16 arrests these cells in the G 1 phase of the cell cycle and their analysis. One-fourth of each lysate was mixed with two volumes of RIPA buffer and polyclonal rabbit antiserum against growth is significantly inhibited.
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The U2OS cells were infected with either mutant or wt p16 p16 (Pharmigen) and incubated on ice for 2 h. Antibodyprotein complexes were recovered by incubation with 15 l expressing retroviruses ( Figure 1 ) and grown in medium containing G418 (Table 1 ). The wt p16 protein inhibited colony of protein G-protein A-agarose (Oncogene Sciences, Cambridge, MA, USA) or protein-A sepharose (Pharmacia LKB growth greater than 30-fold compared to the empty virus control. The p16 mutants E120K and R144C inhibited growth Biotechnology, Piscataway, NJ, USA) followed by three washes with NP-40 lysis buffer. The recovered proteins were approximately 15-to 20-fold. The G101W mutant inhibited growth slightly (0.25-fold) and H83Y was unable to inhibit mixed with sample buffer, boiled for 5 min, analyzed by SDS-PAGE (polyacrylamide gel electrophoresis), treated for fluorgrowth of the cells. Of the three deletion mutants, DA4 and D141 were tested. DA4 was unable to inhibit growth ography using FluoroEnhance (Research Products, Mount Prospect, IL, USA) and exposed to Kodak XO-MAT AR film (Table 1 ). In contrast, D141 inhibited growth approximately five-fold. A parallel infection of another osetosarcoma cell (Kodak, Rochester, NY, USA).
For half-life experiments, cells were labeled for 30 min as line, SAOS-2, that lacks a functional pRb, demonstrated that the mutant p16 retrovirus stocks contained the same number described above and chased with medium containing excess nonradioactive methionine and cysteine for 0, 0.5, 1.0, 2.0, or slightly more G418-R CFU per infection than the wild-type (data not shown); therefore, differences in growth inhibition 4.0 and 8.0 h post-labelling. Cell lysates were prepared in RIPA buffer and immunoprecipitations performed as described were not due to significant differences in the virus stock titers. To ensure that each recombinant retrovirus vector above. Relative intensity of the bands was determined as described previously 37 and half-lives calculated by curve expressed its respective p16 protein, we examined COS-1 cells transiently transfected with the retrovirus expression vecfitting. tors ( Figure 2 ). The wild-type p16 and mutant proteins were detected using a polyclonal antiserum made against the fulllength p16 protein (Figure 2a ). The deletion mutants migrated
Reverse-transcription polymerase chain reaction (RT-PCR) analysis more rapidly than the wild-type protein as expected (Figure 2a ). The endogenous monkey p16 protein was not Total RNA was isolated from cells using Trizol reagent (Gibco/BRL) as described by the manufacturer. For each sam- trophoresed on a 3% agarose gel and blotted on to Hybond against the last 20 carboxy-terminal amino acid residues (137-156) of p16. This antibody was unable to detect the deletion mutants as expected (Figure 2b ; DA4, D136 and D141). The expression levels of the mutant p16 proteins H83Y, G101W, DA4, D141 and D136 were examined in two tem like the wt p16 protein. 33 The mutant G101W interacted or three separate transient transfection experiments and were almost as efficiently as the wt p16, but was 50 times less effecfound, in each case, to be expressed at levels lower than the tive in inhibition of CDK4 kinase activity. 33 To determine the wild-type protein. Also, this was observed in stably transforability of these proteins to interact in cells, we immunoprecipmed COS-1 cells that were analyzed by immunoprecipitation itated radiolabeled extracts from COS-1 cells stably expressing rather than immunoblot analysis (Figure 3 ). Other antisera each of the p16 proteins using a polyclonal anti-p16 antibody. made against the p16 protein revealed the same expression As observed for transient expression, we found that the mutant patterns (data not shown) indicating that possible antigenic proteins were expressed at levels lower than the wt p16 differences between the mutant proteins were not responsible (Figure 3a and b; 3 and 30 day exposures, respectively). The for differences in the levels of protein detected. The levels of CDK4 and CDK6 proteins co-immunoprecipitated with wt H83Y and G101W expression were significantly higher than p16, E120K and R144C (Figure 3a and b) . These proteins were that of D141, which was very difficult to detect (Figure 2 ), but not present in the control cells stably transformed with the D141 expression inhibited growth more efficiently than H83Y empty vector (Figure 3a and b) indicating they are specifically and G101W (Table 1 ). This indicates that the H83Y and co-immunoprecipitating with p16. CDK4 and CDK6 were not G101W mutations completely abrogate p16 function and sugco-immunoprecipitated with H83Y, DA4 or G101W gests that their lower level of expression than wt p16 does not (Figure 3b ). Immunoprecipitation of these lysates with antiaccount for their inability to inhibit cell growth. These data serum against the CDK4 protein co-immunoprecipitated wt demonstrated that the recombinant retrovirus vectors p16, but not the mutants H83Y, G101W and DA4 (data not expressed the expected proteins and that wild-type, but not shown). Detection of the p16 deletion mutants D136 and mutant p16, inhibited the growth of a pRb-positive cell line. D141 was difficult due to their low level of expression and comigration with non-specifically immunoprecipitated proteins (Figure 3a and b) . These results strongly suggest that the
Mutant p16 proteins do not interact with CDK4
H83Y, G101W and DA4 mutant proteins cannot inhibit growth of the U2OS cells as effectively as wt p16 because of Our previous study showed that H83Y and DA4 were not able to interact with the CDK4 subunit in the yeast two-hybrid sysinefficient binding to the CDK4 and 6 proteins. (Figures 2 and 3 ). This
may be due to reduced protein stability for the latter group of
mutations. Recently, a study showed that certain p16
mutations in lung cancer cell lines resulted in expression of
proteins with reduced half-lives. 39 These included H83Y and a splice site mutation that resulted in the loss of the last four a p16 status as determined previously: HSB-2 and CEM, 18 proteins (Figure 4) . The wt p16 was very stable with a half-life of approximately 270 min (Figure 4 ). In contrast, H83Y and G101W were relatively unstable with half-lives of about 85 the growth of HSB-2 which lacks both p16 and pRb was not affected by overexpression of p16 (Table 2) , demonstrating and 130 min, respectively (Figure 4) . that functional pRb is required for growth inhibition.
To verify that the transduced p16 gene was expressed in the leukemia cell lines after retroviral infection, we prepared total Human leukemia cell line growth is inhibited by wildtype p16
INK4A expressed by recombinant retrovirus RNA from the HSB-2 and K562 cell lines 2 and 16 days postinfection. The 16 day post-infection samples were selected in the presence of G418 in liquid culture. By this time-point, few To determine if loss of p16 plays a possible role in the development of leukemias, we examined the ability of exogenously K562 cells survived, due to the inhibition of growth by p16 expression, whereas the pRb-minus HSB-2 cells grew well. expressed p16 to inhibit the growth of several cell lines. Each cell line was infected with either an empty retrovirus or one
The RNA samples were treated with RNase-free DNase and tested for expression by RT-PCR using primers specific for the expressing wt p16, and these cells were plated in soft agar containing G418 to select for infected cells. The growth of human p16 gene. Also, as a control, we examined ␤-actin expression. The PCR was performed three times for each samthe cell lines CEM, K562 and NB-4, which are homozygously deleted for p16, was dramatically reduced ( Table 2 ). The CEM ple to verify that negative results were not due to failure of the PCR. A representative Southern blot is presented in Figure 5 . and K562 cell lines have an intact pRb gene (Table 2) , and the strong inhibition of NB-4 growth indicates that it must
As expected, cells that were infected with empty retrovirus (−) did not express detectable levels of p16, but were positive express a functional pRb, although this was not determined previously (Table 2) . We found that mutant forms of p16 for ␤-actin at 2 and 16 days post-infection (lanes 1, 3, 5 and 7; Figure 5 ). In contrast, both HSB-2 and K562 cells that were (H83Y and DA4) did not inhibit the growth of NB-4 as compared to the wild-type and were similar to the empty virus, infected with p16 containing retrovirus (+) were positive for the p16 and ␤-actin expression after 2 days (lanes 2 and 6, demonstrating that functional p16 protein must be overexpressed for growth suppression (data not shown). As expected, Figure 5 ). After 16 days of selection in G418, the HSB-2 cells
Figure 5
RT-PCR analysis of p16 expression in leukemia cell lines. The cell lines HSB-2 and K562 were infected with retroviruses either lacking (−) or containing (+) the wild-type p16 gene. Total RNA was Figure 4 Half-lives of wild-type and mutant p16 proteins. COS-1 cells stably expressing the wild-type, H83Y or G101W p16 proteins prepared on days 2 and 16 post-infection. The day 16 sample was cultured for 14 days in G418 to select for only those cells infected were plated at equal numbers and radiolabeled for 30 min and chased with 'cold' methionine for 0, 0.5, 1.0, 2.0, 4.0 and 8.0 h. Lysates were by the retrovirus. RT-PCR analysis was performed for both the p16 and ␤-actin mRNAs (positions indicated at the right of the figure). The immunoprecipitated with polyclonal anti-serum against the full-length p16 protein (Pharmingen); electrophoresed through a 12.5% polyacrynegative (N) and positive (P) controls consisted of PCR reactions either lacking a cDNA template or using a cDNA prepared from the cervical lamide gel and fluorographed. Autoradiographs were analyzed by densitometry and the results were used to determine the half-life (T1/2) cancer cell line, HeLa, respectively. The products were examined by Southern blot analysis using internal oligonucleotides specific for of each protein by curve fitting. Abbreviations as described in legend for Figure 1 .
each product.
expressed easily detected levels of p16, but K562 did not addition, H83Y did not bind CDK4 or CDK6 and its half-life was about three times shorter than wt p16 (Figure 4 ). This (lanes 4 and 8, respectively; Figure 5 ). These samples were positive for ␤-actin expression indicating that failure to reduction in half-life is similar to that reported previously. 39 Our results verify those of the previous study, but eliminate observe p16 was not due to problems with the cDNA template. The negative control (N, lane 9; Figure 5 ) did not conany possible cell line differences, since we compared the H83Y mutant and wt p16 in COS-1 cells. Like H83Y, DA4 tain any cDNA and the positive control (P, lane 10; Figure 5 ) was a cDNA prepared from the total RNA of the cervical canwas unable to inhibit cell growth due to its failure to interact with CDK4 both in vitro and in cells (Figure 3 ). Both the H83Y cer cell line, HeLa. The K562 cells that grew during the selection had apparently eliminated the expression of the p16 gene, and DA4 mutations affect the integrity of the ankyrin repeats which are critical for protein-protein interactions. 33, 47 Further but maintained expression of the neomycin gene that confers resistance to G418. These results demonstrated that exogenstudies are necessary to determine if failure to bind to CDK4 or CDK6 results in decreased protein stability of p16. ous expression of wild-type p16 in leukemia cell lines with homozygous deletions of the gene occurred after retroviral Ambiguities arise when the activity of G101W is examined by various assays. It binds CDK4 in yeast, but does not inhibit infection.
CDK4 activity efficiently. Fifty-fold higher molar concentrations were required for wild-type levels of inhibition. 33 Forced expression in cells leads to a mild growth inhibition Discussion (Table 1) ; however, it arrests cells in G 1 almost as effectively as the wt p16. 41 This mutation was reported to disrupt binding To test the hypothesis that the p16 gene is a growth suppressor in human leukemia cells, we utilized a retroviral expression to CDK4, but not CDK6; 44 however, we did not detect efficient binding to either CDK4 or CDK6 in cells (Figure 3 ). system to overexpress both wild-type and mutant forms of the p16 protein in various human leukemia cell lines. We first Structural characterization of G101W by NMR and circular dichroism indicate the mutation may result in a structural perexamined the effect of the wt and mutant p16 genes in the osteosarcoma cell line U2OS. The growth of these cells is draturbation. 48 Recent studies demonstrated G101W is a temperature-sensitive mutant that binds to CDK4 and CDK6, simimatically inhibited by overexpression of a number of CDKIs including p16 38 and allowed us to test the efficacy of the retrolar to wt p16, at 30°C, but is nonfunctional at 42°C in vitro. 45 At 34°C, G101W arrests cells in G 1 as efficiently as wt p16; viruses.
Our initial in vitro study of the mutant p16 proteins sugbut at 40°C, the arrest is substantially reduced. 45 In cells at 37°C, G101W shows a two-fold reduction in half-life when gested that two groups of inhibitors existed: those that bound to CDK4 and inhibited kinase activity, which included wt p16, compared to wt p16 ( Figure 4) . The temperature sensitivity, reduced half-life and inefficient binding of CDK4 and CDK6 E120K, R144C, D136 and D141, and those that did not bind to CDK4 or inhibit kinase activity and included H83Y, may explain why G101W only inhibits growth very slightly at 37°C (Table 1) . Under normal cellular conditions this G101W and DA4 (Figure 1) . 33 The first group would be predicted to inhibit growth of cells strongly and the second would mutation impairs p16 function and is strongly implicated in the development of melanoma. 12 Further studies are required not. In contrast, the growth suppression data in U2OS cells (Table 1 ) indicated that the mutants should be grouped into to determine if lower temperature returns G101W to a normal conformation, thus resulting in both increased protein stability three classes: strong, intermediate and non-functional suppressors of growth. The strong suppressors, wt p16, and and binding of G101W to CDK4 and CDK6. Our in vitro study indicated that the COOH-terminal mutants E120K and R144C, inhibited growth by 30-, 20-and 15-fold, respectively, and bound efficiently to CDK4 and deletion mutants retain the ability to bind to CDK4 and inhibit its activity almost as efficiently as the wt p16. 33 In contrast, CDK6 (Figure 3) . The intermediate suppressors, G101W and D141, inhibited growth by 0.25-and five-fold, respectively, D141 is six times less efficient at inhibiting cell growth (Table 1) . We were not able to verify that D141 binds CDK4 and did not bind detectable levels of CDK4 or CDK6. The non-functional suppressors, H83Y and DA4, did not inhibit and CDK6 in cells, because it was expressed at very low levels (Figures 2 and 3 ). Although we have not determined the halfthe growth of cells at all and were unable to bind CDK4 or CDK6. Those mutations (G101W, H83Y and DA4) that affeclife of the D141 deletion mutant, studies of a lung cancer cell line with a splice site mutation indicated that loss of the last ted the highly conserved amino acid residues in the ankyrin repeats altered p16 function the most. 33, [40] [41] [42] [43] [44] [45] [46] four amino acid residues of p16 significantly reduces the protein's half-life. 39 The weaker growth suppression by D141 is The E120K and R144C mutants significantly inhibited cell growth when overexpressed, suggesting these changes were most likely a result of a reduced half-life and under normal cellular conditions D141 does not accumulate to levels high not deleterious to the function of p16. It is possible that these changes may affect the function of p16 protein to inhibit cell enough to inhibit growth as efficiently as wt p16. The 20-amino acid COOH-terminal region of p16 is absent in the cycle and growth in the context of normal expression levels and patterns and were not revealed by the assays used in our highly homologous p15 protein (Figure 1 ) which also inhibits cell growth; 49 therefore, this region is probably not essential study. Alternatively, since these mutations either do not involve conserved amino acid residues or are outside of the for the growth inhibitory function of either protein. Of note, the levels of wt p16 protein are relatively constant throughout ankyrin repeats (Figure 1 ), they may be polymorphisms and are not associated with disease. the cell cycle with a peak at S-phase. 50 In contrast, p15 levels are upregulated by either transforming growth factor beta or Recently, a study of lung cancer cell lines H596 and Calu-3, that express wild-type or mutant H83Y p16, respectively, cell-to-cell contact. 34 Currently, we are elucidating the role of the COOH-terminal tail in regulating the stability of these showed that H83Y was much less stable than the wt p16 (40 vs 200 min) protein. 39 Also, the H83Y protein did not bind to proteins in cells and its biological significance. Loss of p16 is strongly implicated in the development of CDK4 or CDK6, suggesting that it may not inhibit cell cycle progression or growth. 39 Our results indicated H83Y is unable leukemias, particularly T cell ALLs; however, it has not been demonstrated that exogenous expression of p16 has a growth to inhibit cell growth when exogenously expressed in cells. In
